gestonorone caproate

Gestonorone caproate is a long-acting, potent synthetic progestogen (progestin) structurally related to progesterone. It is used primarily in the palliative treatment of benign prostatic hyperplasia and endometrial cancer, administered by intramuscular injection typically once a week. Gestonorone caproate acts as a pure progestogen with no androgenic, anabolic, antiandrogenic, estrogenic, antiestrogenic, glucocorticoid, or mineralocorticoid effects. Its mechanism involves strong agonism at the progesterone receptor and marked antigonadotropic activity—suppressing gonadal production of sex hormones such as testosterone and estradiol. Developed by Schering in the 1960s and marketed since at least 1968 under brand names including Depostat and Primostat[1][3][7].

Brand names

DepostatPrimostat

Other names

gestronol hexanoatenorhydroxyprogesterone caproate